tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Biogen (BIIB) and Blueprint Medicines (BPMC)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sanofi (SNYNFResearch Report), Biogen (BIIBResearch Report) and Blueprint Medicines (BPMCResearch Report).

Sanofi (SNYNF)

In a report released today, Emily Field from Barclays maintained a Buy rating on Sanofi, with a price target of EUR115.00. The company’s shares closed last Thursday at $108.00, close to its 52-week high of $114.90.

Field has an average return of 2.5% when recommending Sanofi.

According to TipRanks.com, Field is ranked #3626 out of 8406 analysts.

Currently, the analyst consensus on Sanofi is a Moderate Buy with an average price target of $111.30, representing a 3.1% upside. In a report released today, Bank of America Securities also maintained a Buy rating on the stock with a $64.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Biogen (BIIB)

Wedbush analyst Laura Chico reiterated a Hold rating on Biogen today and set a price target of $263.00. The company’s shares closed last Monday at $306.87, close to its 52-week high of $319.74.

According to TipRanks.com, Chico is a 2-star analyst with an average return of -0.2% and a 48.4% success rate. Chico covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Ultragenyx Pharmaceutical, and Apellis Pharmaceuticals.

Currently, the analyst consensus on Biogen is a Moderate Buy with an average price target of $330.90, representing a 6.8% upside. In a report issued on May 15, Bank of America Securities also maintained a Hold rating on the stock with a $320.00 price target.

Blueprint Medicines (BPMC)

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Blueprint Medicines, with a price target of $75.00. The company’s shares closed last Monday at $56.25.

According to TipRanks.com, Moussatos is ranked #2135 out of 8406 analysts.

Blueprint Medicines has an analyst consensus of Moderate Buy, with a price target consensus of $71.71, a 29.8% upside from current levels. In a report released today, Needham also maintained a Buy rating on the stock with a $67.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SNYNF:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles